Patents by Inventor Guey-Chuen Perng

Guey-Chuen Perng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11883418
    Abstract: A compound TSYI-ZAC (Zhankuic acid C) used in a method for treating dengue virus infection, in which a pharmaceutical composition can further comprise a 4,7-dimethoxy-5-methyl-1,3-benzodioxole compound capable of inhibiting dengue virus infection by down-regulating an expression of IL-6 and IL-8, and increasing a secretion of IFN-?.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: January 30, 2024
    Assignee: SYI BIOTECHNOLOGY CO., LTD.
    Inventors: Chia-Chang Chen, Guey-Chuen Perng, Hsiu-Man Lien, Yi-Ju Chen
  • Publication number: 20230285415
    Abstract: A compound TSYI-ZAC (Zhankuic acid C) used in a method for treating dengue virus infection, in which a pharmaceutical composition can further comprise a 4,7-dimethoxy-5-methyl-1,3-benzodioxole compound capable of inhibiting dengue virus infection by down-regulating an expression of IL-6 and IL-8, and increasing a secretion of IFN-?.
    Type: Application
    Filed: June 8, 2022
    Publication date: September 14, 2023
    Inventors: Chia-Chang Chen, Guey-Chuen Perng, Hsiu-Man Lien, Yi-Ju Chen
  • Publication number: 20230233629
    Abstract: A method to treat hepatoma with dengue viruses which infect liver tumor stem cells for annihilation of hepatocellular carcinoma tissues. The liver tumor stem cells expressing the biomarker of CD133 in a tumor part are the objects infected by dengue viruses preferentially and killed due to specific protein expressions for suppression of hepatoma.
    Type: Application
    Filed: July 22, 2022
    Publication date: July 27, 2023
    Inventors: Chia-Chang Chen, Guey-Chuen Perng, Hsiu-Man Lien, Yi-Ju Chen
  • Patent number: 6838279
    Abstract: Disclosed is an HSV-1-derived vector containing a DNA having a functional LAT promoter, or operative fragment thereof, a deletion in both copies of the HSV-1 LAT gene, and a deletion in both copies of the HSV-1 ICP34.5 gene. The HSV-1-derived vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir. Alternatively, the HSV-1-derived vectors contain at least one transcriptional unit of a LAT promoter sequence operatively linked to a nucleic acid encoding a preselected protein. In some embodiments, the preselected protein is a nucleotide sequence encoding a polypeptide toxic for cells expressing the vector, for example, human interferon-?. Also, disclosed are kits for expressing in a mammalian cell a gene encoding a preselected protein, and mammalian cells containing the HSV-derived vectors.
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: January 4, 2005
    Assignee: Cedars-Sinai Medical Center
    Inventors: Steven L. Wechsler, Anthony B. Nesburn, Guey-Chuen Perng, John S. Yu, Keith L. Black
  • Patent number: 6774119
    Abstract: Disclosed is a method of selectively inhibiting the growth of malignant cells in mammals, including humans. The method selectively inhibits the growth of malignant cells of all varieties, and is particularly useful in treating brain tumors and other malignancies of the central nervous system. The method employs HSV-1-derived vectors containing a DNA having a deletion in both copies of the LAT gene and both copies of the ICP34.5 gene of HSV-1. The vectors are delivered to malignant cells either in vivo or in vitro, in accordance with the method. The HSV-1-derived expression vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir.
    Type: Grant
    Filed: April 26, 1999
    Date of Patent: August 10, 2004
    Assignee: Cedars-Sinai Medical Center
    Inventors: Steven L. Wechsler, Anthony B. Nesburn, Guey-Chuen Perng, John S. Yu, Keith L. Black
  • Publication number: 20020098170
    Abstract: Disclosed is a method of selectively inhibiting the growth of malignant cells in mammals, including humans. The method selectively inhibits the growth of malignant cells of all varieties, and is particularly useful in treating brain tumors and other malignancies of the central nervous system. The method employs HSV-1-derived vectors containing a DNA having a deletion in both copies of the LAT gene and both copies of the ICP34.5 gene of HSV-1. The vectors are delivered to malignant cells either in vivo or in vitro, in accordance with the method. The HSV-1-derived expression vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir.
    Type: Application
    Filed: November 29, 2001
    Publication date: July 25, 2002
    Inventors: Steven L. Wechsler, Anthony B. Nesburn, Guey-Chuen Perng, John S. Yu, Keith L. Black
  • Patent number: 5324630
    Abstract: A chromosomal gene of Borrelia burgdorferi which encodes a conserved antigen of approximately 79 kD has been isolated and sequenced. The chromosomal gene, the gene product, and antibodies to the gene product may be used in diagnostic methods for the detection of Borrelia burgdorferi infection. The antigen and fragments thereof are suitable for use in vaccine compositions and methods.
    Type: Grant
    Filed: June 28, 1991
    Date of Patent: June 28, 1994
    Assignee: The Regents of the University of California
    Inventors: Rance B. LeFebvre, Guey-Chuen Perng